/
CDIO
$2.01-$0.15 (-6.94%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.4M
3M shares
52-week range
$0.97 – $7.91
15% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Change$-112.59
Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
www.cdio.ai- Employees
- 17
- IPO / List date
- Oct 26, 2022
- HQ
- CHICAGO, IL
Held by traders on TradeandTell
No one on the platform currently holds CDIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 15,348 | $29.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-05-13 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CDIO yet.
